Arovella Receives R&D Tax Rebate of $3,210,000
MELBOURNE, AUSTRALIA 23 September 2025: Arovella Therapeutics Ltd (ASX: ALA) ACN 090 987 250 (Arovella or the Company) is pleased to announce that it has received an FY2025 R&D Tax Incentive refund of $3.21 million. These funds further strengthen Arovella’s cash position as it progresses development if its lead asset, ALA-101, towards first-in-human clinical trials.
CEO and Managing Director, Dr Michael Baker, noted, “With the R&D tax rebate secured, Arovella is in an excellent financial position to commence the first-in-human clinical trial for ALA-101, targeting CD19-positive lymphoma and leukaemia. We anticipate lodging the IND application in time for the FDA to accept it this calendar year, allowing the ALA-101 clinical trial to commence soon after.”
The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with cash refunds for 43.5-48.5% of eligible expenditure on research and development activities.
